These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 20469779

  • 1. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK, Bansal A, Khan ZY.
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [Abstract] [Full Text] [Related]

  • 2. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 3. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 4. Insulin therapy in type 2 diabetes: what is the evidence?
    van Avendonk MJ, Rutten GE.
    Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375
    [Abstract] [Full Text] [Related]

  • 5. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 6. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 7. Insulin glargine (Lantus).
    Owens DR, Griffiths S.
    Int J Clin Pract; 2002 Nov; 56(6):460-6. PubMed ID: 12166545
    [Abstract] [Full Text] [Related]

  • 8. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K, Janssen MM, Keulen ET, Jacobs MA, Popp-Snijders C, Snoek FJ, Heine RJ.
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [Abstract] [Full Text] [Related]

  • 9. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 10. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 11. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [Abstract] [Full Text] [Related]

  • 12. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 13. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 14. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
    Rhoads GG, Kosiborod M, Nesto RW, Fonseca VA, Lu SE, Zhang Q, Foody JM.
    Am J Cardiol; 2009 Oct 01; 104(7):910-6. PubMed ID: 19766755
    [Abstract] [Full Text] [Related]

  • 15. Addressing hyperglycemia from hospital admission to discharge.
    Moghissi ES.
    Curr Med Res Opin; 2010 Mar 01; 26(3):589-98. PubMed ID: 20078323
    [Abstract] [Full Text] [Related]

  • 16. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
    Diabet Med; 2009 Oct 01; 26(10):1027-32. PubMed ID: 19900235
    [Abstract] [Full Text] [Related]

  • 17. [Comparison on efficacy and safety of two regimens for treatment of type 2 diabetes mellitus: glargine plus metformin versus neutral protamine hagedorn plus metformin].
    Hu M, Luo Y, Zhang L, Yang X, Zhang H.
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Jun 01; 27(3):622-5. PubMed ID: 20649032
    [Abstract] [Full Text] [Related]

  • 18. Benefits of a simple glycaemic protocol in an orthopaedic surgery ward: a randomized prospective study.
    Schroeder JE, Liebergall M, Raz I, Egleston R, Ben Sussan G, Peyser A, Eldor R.
    Diabetes Metab Res Rev; 2012 Jan 01; 28(1):71-5. PubMed ID: 21584922
    [Abstract] [Full Text] [Related]

  • 19. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR, Lurie A, Baldwin D.
    Diabetes Technol Ther; 2006 Dec 01; 8(6):609-16. PubMed ID: 17109592
    [Abstract] [Full Text] [Related]

  • 20. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
    Siegmund T, Weber S, Blankenfeld H, Oeffner A, Schumm-Draeger PM.
    Exp Clin Endocrinol Diabetes; 2007 Jun 01; 115(6):349-53. PubMed ID: 17701878
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.